Literature DB >> 6137859

Residual and acute effects of flurazepam and triazolam in normal subjects.

C Gorenstein, V Gentil.   

Abstract

Residual and acute effects of flurazepam and triazolam were studied in two double-blind, crossover, placebo controlled, single-dose experiments. Psychological and physiological effects were determined 10 h after night administration (flurazepam 30 mg and triazolam 0.5 mg), and for 6 h after morning ingestion (flurazepam 15 mg and triazolam 0.25 mg). Both drugs produced similar "hangover" effects, impairing motor performance and increasing sleepiness on the following morning. After morning administration pronounced sedative effects were found with triazolam, while flurazepam effects were mild and hard to distinguish from placebo. The clinical relevance of these findings is discussed, suggesting that these drugs may be conceived as belonging to two different types of hypnotic agents.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137859     DOI: 10.1007/bf00432125

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Efficacy and residual effect evaluation of a new hypnotic, triazolam.

Authors:  W Veldkamp; R N Straw; C M Metzler; H V Demissianos
Journal:  J Clin Pharmacol       Date:  1974 Feb-Mar       Impact factor: 3.126

2.  Blood level profile in man following chronic oral administration of flurazepam hydrochloride.

Authors:  S A Kaplan; J A de Silva; M L Jack; K Alexander; N Strojny; R E Weinfeld; C V Puglisi; L Weissman
Journal:  J Pharm Sci       Date:  1973-12       Impact factor: 3.534

3.  The residual effects of flurazepam.

Authors:  A J Bond; M H Lader
Journal:  Psychopharmacologia       Date:  1973-09-28

4.  Residual effects of hypnotics.

Authors:  A J Bond; M H Lader
Journal:  Psychopharmacologia       Date:  1972

5.  The effects of triazolam and nitrazepam on sleep quality, morning vigilance and psychomotor performance.

Authors:  I Hindmarch; C A Clyde
Journal:  Arzneimittelforschung       Date:  1980

6.  The acute effects of oral (--)-tryptophan in human subjects.

Authors:  M H Greenwood; M H Lader; B D Kantameneni; G Curzon
Journal:  Br J Clin Pharmacol       Date:  1975-04       Impact factor: 4.335

7.  The pharmacokinetics of midazolam in man.

Authors:  M T Smith; M J Eadie; T O Brophy
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

8.  Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium.

Authors:  A Malpas; A J Rowan; C R Boyce; D F Scott
Journal:  Br Med J       Date:  1970-06-27

9.  Residual effects of hypnotics: triazolam, flurazepam, and nitrazepam.

Authors:  C Ogura; K Nakazawa; K Majima; K Nakamura; H Ueda; Y Umezawa; W M Wardell
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

10.  Sedative-hypnotics and human performance.

Authors:  L C Johnson; D A Chernik
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  4 in total

1.  Acute reversal of flunitrazepam effects by Ro 15-1788 and Ro 15-3505: inverse agonism, tolerance, and rebound.

Authors:  V Gentil; S Tavares; C Gorenstein; C Bello; L Mathias; G Gronich; J Singer
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Benzodiazepines and caffeine: effect on daytime sleepiness, performance, and mood.

Authors:  L C Johnson; C L Spinweber; S A Gomez
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Study of the potential reversal of triazolam memory and cognitive deficits by RU 41 656 in healthy subjects.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.